People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

62.52USD
30 Mar 2015
Change (% chg)

$-0.81 (-1.28%)
Prev Close
$63.33
Open
$63.60
Day's High
$64.21
Day's Low
$61.97
Volume
1,410,414
Avg. Vol
1,566,755
52-wk High
$75.17
52-wk Low
$38.49

Search Stocks

Bloom, Floyd 

Dr. Floyd E. Bloom M.D. is an Independent Director of Alkermes Plc. Dr. Bloom is a founder of Alkermes, Inc. and from 1987 to September 16, 2011, served on the Alkermes, Inc. board of directors. Dr. Bloom has been active in neuropharmacology for more than 35 years, holding positions at Yale University, the National Institute of Mental Health, The Salk Institute, and The Scripps Research Institute. From 1983 to February 2005, Dr. Bloom was the Chairman of the Neuropharmacology Department at The Scripps Research Institute and is now Professor Emeritus. Dr. Bloom served as Editor-in-Chief of Science from 1995 to May 2000. He is a member of the National Academy of Science, the Institute of Medicine, the Royal Swedish Academy of Science and the American Philosophical Society. He serves on the Veteran's Administration—Gulf War Veterans Illness Research Advisory Committee and is an Emeritus Trustee for the Board of Trustees at Washington University in St. Louis. Dr. Bloom is a director of LZ Therapeutics and AgeneBio, Inc., both privately held biopharmaceutical companies. Dr. Bloom also serves on the Scientific Advisory Boards of aTyr Pharma, a privately held pharmaceutical company and RiverVest, a private venture partnership focusing on life sciences. Dr. Bloom served as a member of the board of directors of Elan from 2007 to 2009. Dr. Bloom is a distinguished scientist and long-standing member of various scientific societies, including the National Academy of Sciences. His scientific knowledge makes him a resource to our research and development and commercial teams and a reference point for other directors. Dr. Bloom's service on other company boards provides experience relevant to good corporate governance practices. As a founder of Alkermes, Inc., Dr. Bloom brings a historical perspective to the Board.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Pops

8,696,650

Shane Cooke

3,912,100

James Frates

2,095,130

Gordon Pugh

1,965,720

Kathryn Biberstein

2,488,720

Rebecca Peterson

--
As Of  30 Mar 2014
Search Stocks